R W Shafer|T C Merigan - JoVE Visualize

Showing results (261-270 of 289) with videos related to

Pageof 29

Sort By:

Annals of Internal Medicine|November 1, 1984

Survival in chronic hepatitis B. An analysis of 379 patientsJ I Weissberg, L L Andres, C I Smith, et al.

Nature Medicine|July 1, 1996

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arraysM J Kozal, N Shah, N Shen, et al.

Blood|February 15, 1989

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferonS L Brown, R A Miller, S J Horning, et al.

Journal of Virology|May 1, 1987

Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.

The Journal of Infectious Diseases|January 1, 1997

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.

The Journal of Infectious Diseases|January 1, 1995

Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessmentR W Shafer, P M Small, C Larkin, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.

AIDS (London, England)|March 1, 1996

Predictors of survival in HIV-infected tuberculosis patientsR W Shafer, A B Bloch, C Larkin, et al.

Diabetologia|August 1, 1981

Human leukocyte interferon treatment of two children with insulin dependent diabetesK H Rand, A L Rosenbloom, N K Maclaren, et al.

The Journal of Infectious Diseases|June 1, 1996

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.

Pageof 29

Showing results (261-270 of 289) with videos related to

Sort By:

Pageof 29

Annals of Internal Medicine|November 1, 1984

Survival in chronic hepatitis B. An analysis of 379 patientsJ I Weissberg, L L Andres, C I Smith, et al.

Nature Medicine|July 1, 1996

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arraysM J Kozal, N Shah, N Shen, et al.

Blood|February 15, 1989

Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferonS L Brown, R A Miller, S J Horning, et al.

Journal of Virology|May 1, 1987

Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte responsesJ W Torseth, G H Cohen, R J Eisenberg, et al.

The Journal of Infectious Diseases|January 1, 1997

Cytomegalovirus gB genotype distribution differs in human immunodeficiency virus-infected patients and immunocompromised allograft recipientsL Rasmussen, C Hong, D Zipeto, et al.

The Journal of Infectious Diseases|January 1, 1995

Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessmentR W Shafer, P M Small, C Larkin, et al.

Journal of Immunology (Baltimore, Md. : 1950)|February 11, 1999

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)C M Gray, J Lawrence, J M Schapiro, et al.

AIDS (London, England)|March 1, 1996

Predictors of survival in HIV-infected tuberculosis patientsR W Shafer, A B Bloch, C Larkin, et al.

Diabetologia|August 1, 1981

Human leukocyte interferon treatment of two children with insulin dependent diabetesK H Rand, A L Rosenbloom, N K Maclaren, et al.

The Journal of Infectious Diseases|June 1, 1996

A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.

Pageof 29